26.01.2017 20:56:00
|
Missouri Supreme Court Denies Requests to Delay Talc-Related Cancer Trials
ST. LOUIS, Jan. 26, 2017 /PRNewswire/ -- The Missouri Supreme Court has denied requests by Johnson & Johnson (NYSE:JNJ) and its supplier of baby powder talc to delay upcoming trials over allegations that the company's talc-based products led to the development of ovarian cancer in some women. That means the next trial will go forward on Feb. 6 in St. Louis.
Attorneys for J&J and Imerys Talc America had asked the state Supreme Court to deny the jurisdiction of the 22nd Circuit Court in St. Louis to hear the cases, since most of the plaintiffs with pending claims are not Missouri residents. The plaintiffs' attorneys countered by pointing out those individuals are legally and properly before that court and that both defendants have a presence in the state of Missouri. In the latest blow to the defendants, the Supreme Court rejected their motions on Jan. 24. An appeals court had also denied the motions earlier this month.
Last year, St. Louis juries returned three separate verdicts of $70 million, $72 million and $55 million for cancer victims who sued New Jersey-based J&J.
The cases claim that numerous scientific studies have shown the link between ovarian cancer and genital use of talc-containing products manufactured and marketed by J&J, including Johnson's Baby Powder and Shower to Shower. Attorneys for the plaintiffs allege the companies knew about the dangers of talcum powder for decades, but attempted to suppress and dismiss the research while refusing to provide warning labels on talc-containing products.
"The Missouri Supreme Court has affirmed the constitutional rights of these women and families to file these claims in a central location with well-educated jurors, a fair-minded judiciary, and efficient court system," said Ted Meadows, attorney for the plaintiffs and principal at the Beasley Allen Law Firm in Montgomery, Alabama. "J&J has known about the risk and the link between talcum powder and ovarian cancer for a long time. We have the world's leading clinical researchers and scientists on the subject testifying to the link between talc and ovarian cancer. We have the internal company documents, the testimony, and the evidence. And we can show and have shown that J&J has been trying to doctor that evidence for many years."
In the U.S., ovarian cancer affects about 24,000 women a year and is the fifth-leading cause of cancer death for women. Medical experts estimate that more than 14,000 women die from talc-related ovarian cancer each year, and two scientific studies have found that nearly 10 percent of the new ovarian cancer cases reported annually are caused by the genital use of talcum powder.
Headquartered in Montgomery, Alabama, Beasley Allen is comprised of more than 70 attorneys and 200 support staff. One of the largest plaintiffs' law firms in the country, Beasley Allen is a national leader in civil litigation, with verdicts and settlements in excess of $26 billion. Beasley Allen was one of only 12 firms in the nation named by Law360 to its Most Feared Plaintiffs Firms list in 2015, and the firm was included on the National Law Journal Midsize Law Firm Hot List and the NLJ Elite Trial Lawyers List in 2014. For more information about our firm, please visit our website at www.beasleyallen.com.
Media Contact:
Helen Taylor
(334) 495-1169
(334) 201-2311 voice or text
(800) 898-2034 x169
helen.taylor@beasleyallen.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/missouri-supreme-court-denies-requests-to-delay-talc-related-cancer-trials-300397635.html
SOURCE Beasley Allen
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Johnson & Johnsonmehr Nachrichten
18.12.24 |
Dow Jones 30 Industrial-Papier Johnson Johnson-Aktie: So viel Verlust hätte ein Investment in Johnson Johnson von vor einem Jahr eingebracht (finanzen.at) | |
17.12.24 |
Dow Jones-Handel aktuell: Dow Jones legt zum Handelsende den Rückwärtsgang ein (finanzen.at) | |
17.12.24 |
NYSE-Handel Dow Jones am Dienstagnachmittag mit Abgaben (finanzen.at) | |
17.12.24 |
Dow Jones-Handel aktuell: Dow Jones fällt (finanzen.at) | |
16.12.24 |
Schwacher Handel in New York: Dow Jones schlussendlich in Rot (finanzen.at) | |
11.12.24 |
Angespannte Stimmung in New York: Dow Jones beendet die Mittwochssitzung im Minus (finanzen.at) | |
11.12.24 |
Schwache Performance in New York: Dow Jones notiert nachmittags im Minus (finanzen.at) | |
11.12.24 |
Zuversicht in New York: Dow Jones mit Kursplus (finanzen.at) |